CLASSICAL HODGKIN LYMPHOMA
Clinical trials for CLASSICAL HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new CLASSICAL HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for CLASSICAL HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
First human test of Pfizer's new cancer drug begins
Disease control OngoingThis early-stage study is testing the safety and side effects of a new cancer drug called PF-08046032, both alone and in combination with another immunotherapy drug called sasanlimab. It involves a small group of adults with advanced lymphomas or solid tumors that have spread or …
Matched conditions: CLASSICAL HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Apr 04, 2026 00:20 UTC
-
New drug duo targets stubborn blood cancer
Disease control OngoingThis study is testing whether combining two existing cancer drugs—ibrutinib (a pill) and nivolumab (an IV infusion)—can help people with Hodgkin's lymphoma that has come back or hasn't responded to previous treatments. The goal is to see if this combination can shrink tumors and …
Matched conditions: CLASSICAL HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated Apr 03, 2026 14:43 UTC
-
New hope for advanced Hodgkin's lymphoma patients in china trial
Disease control OngoingThis study is testing whether adding a new immunotherapy drug called camrelizumab to standard chemotherapy (AVD) works better for people with advanced Hodgkin's lymphoma who haven't had treatment before. The trial will enroll 60 patients to see if this combination helps more peop…
Matched conditions: CLASSICAL HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: Henan Cancer Hospital • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC